Ovarian disorder

Related records

Broader conditions (7)

• Disease
• Disease by body system or component
• Endocrine system disorder
• Female reproductive system disorder
• Gonadal disorder
• Human disease
• Reproductive system disorder

Narrower conditions (237)

• 46 XX gonadal dysgenesis
• 46,XX ovarian dysgenesis-short stature syndrome
• Acquired primary ovarian failure
• Acute salpingo-oophoritis
• Anovulation
• Aromatase deficiency
• Ataxia telangiectasia
• Ataxia-telangiectasia with generalized skin pigmentation and early death
• Atypical Meigs syndrome
• Autoimmune oophoritis
• Autoimmune primary ovarian failure
• Benign ovarian mucinous tumor
• Benign ovarian sex cord-stromal tumor
• Benign struma ovarii
• Blepharophimosis-epicanthus inversus-ptosis due to 3q23 rearrangement syndrome
• Blepharophimosis-epicanthus inversus-ptosis due to a point mutation syndrome
• Blepharophimosis-epicanthus inversus-ptosis due to copy number variations
• Blepharophimosis-ptosis-epicanthus inversus syndrome type 1
• Blepharophimosis-ptosis-epicanthus inversus syndrome type 2
• Blepharophimosis, ptosis, and epicanthus inversus syndrome

Trials (76)

• 4K Versus 3D Total Laparoscopic Bilateral Oophorectomy: Tools in Comparison
• 89Zr-MMOT PET Imaging in Pancreatic and Ovarian Cancer Patients
• A Clinical Study on the Feasibility and Safety of Abdominal Endoscopic Single-port Surgery System to Assist Gynecological Day Surgery
• A Comparison of Platinum-based Therapy With TSR-042 and Niraparib Versus Standard of Care (SOC) Platinum-based Therapy as First-line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer
• A Novel Ovarian Reserve Monitoring Algorithm for Patients at Risk of Ovarian Injury From Gonadotoxic Therapy
• A Phase 1 Study of the Safety and Pharmacokinetics of AGS-8M4 in Subjects With Advanced Ovarian Cancer
• A Phase I/II Study of MEDI4736 in Combination With Olaparib in Patients With Advanced Solid Tumors.
• A Phase II, Open-Label Study Evaluating the Effect Of GW786034 In Subjects With Ovarian Cancer
• A Phase-I, Dose Escalation Study of Recombinant Human Interleukin-18 (Sb-485232) Combined With Adoptive Transfer of Vaccine-Primed CD3/CD28-Costimulated Autologous T-Cells Following Lymphodepletion for Adult Patients With Recurrent Ovarian, Fallopian Tube or Primary Peritoneal Cancer
• A Pivotal Bioequivalence Study of DOXIL/CAELYX (Doxorubicin HCL) in Patients With Advanced or Refractory Solid Malignancies Including Patients With Ovarian Cancer
• A Study of MK4827 in Participants With Advanced Solid Tumors or Hematologic Malignancies (MK-4827-001 AM8)
• A Study of MORAb-202 Versus Investigator's Choice Chemotherapy in Female Participants With Platinum-resistant High-grade Serous (HGS) Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
• A Study of the Safety and Pharmacokinetics of AGS-8M4 Given in Combination With Chemotherapy in Women With Ovarian Cancer
• A Study of Trabectedin in Patients With Advanced Ovarian Cancer
• A Study to Evaluate ELU001 in Patients With Solid Tumors That Overexpress Folate Receptor Alpha (FRα)
• AB-1015, an Integrated Circuit T (ICT) Cell Therapy in Patients With Platinum Resistant Epithelial Ovarian Cancer
• Added Value of O-RADS in Evaluation of Ovarian Lesions
• Adebrelimab Combined With Fuzuloparib in the Treatment of Patients With Recurrent Platinum-resistant Ovarian Cancer.
• Anlotinib Combined With Carboplatin/Paclitaxel as First-line Treatment in Patients With Advanced Ovarian Cancer
• Anlotinib Combined With Dose-reduced Olaparib in Patients With Platinum-Sensitive Recurrent Ovarian Cancer